Members
Consortium members and collaborators
Alexandre LehmannCanada
McGill University, Canada·Real-world data, practice-based research network, informing policy, music and plasticity
ContactAlexis ArragonFrance
French Psychedelic Society/ PsychedeliCare·Advocacy for psychedelic therapies, policy work in Europe, general public destigmatization and education
ContactAnya Ragnhildstveit
University of Cambridge·{"Eating disorders",PTSD,suicidality,"IFS therapy"}
ContactDaniel J. KrugerUSA
University at Buffalo; University of Michigan·Survey research, many topics
ContactDiego Pinzon Rubiano
ContactEduardo SchenbergPortugal
Faculty of Medicine, University of Lisbon, Portugal·epistemology, evidence assessments, trial designs, social justice, ethics, indigenous rights, history, mechanisms and more
ContactFarnaz Younessi SisiIran
Yaadmaan Institute for Brain, Cognition and Memory Studies, Tehran, Iran; Cognitive Neurology and Neuropsychiatry Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran·Mechanisms of therapeutic action; Domain-based, neuroscience-informed investigation of psychedelics in neurological conditions
ContactFutaba UmmeuraJapan
Niigata University Graduate School, Tokyo Metropolitan institute of Medicine Science (TMiMS), National Center of Neurology and Psychiatry (NCNP), Japan·Real World Psychedelic Use, Harm Reduction, Online Survey, PAT
ContactGalia J BenitezUSA
Michigan State University·Psychedelics, ritual uses, other uses, indigenous uses, sources, government policies or regulations
ContactJulio Cesar Camargo SilvaCanada
University of British Columbia (UBC) - alumnus·Psychedelic Assisted Therapy (PAT); mental health; psychiatry; treatment methodology; cultural aspects of substance use; community-based research; indigenous rights
ContactKari RockhillUSA
Rocky Mountain Poison & Drug Safety·real-world psychedelic use, epidemiological surveillance, safety monitoring
ContactKatie Pickard
Unlimited Sciences·Real world psychedelic use, evidence-based education, harm reduction, policy change
ContactKristel Carrington
Doctors for Drug Policy Reform·Evidence-based drug policy reform, education, access to psychedelics, decriminalization
ContactLani RoyAustralia
Chair, Australian Multidisciplinary Association Psychedelic Practitioners·harm reduction, preparation, integration, PTSD/sexual abuse - all areas
ContactLucía LevenbergArgentina
Independent·Real world bond with entheogens and psychedelics data, neuroaffirmative and gender affirmative practices in psychedelics, policy change for safe access, ethics, professionals continue education, chronic illness
ContactMahmoud ElmidanyUK
cambridge university hospitals·Qualitative experiences of real world use of psychedelics
ContactMatthew HicksUSA
National University of Natural Medicine; Synaptic Institute·Ketamine, Psilocybin, 5-MeO-DMT research focused on depression, PTSD and accessibility
ContactMichel DorvalCanada
Université Laval, Québec, Canada·Palliative care; psilocybin-assisted therapy; epidemiology
ContactMichelle St. PierreCanada
UBC; BC Centre on Substance Use (BCCSU)·Psychedelics (incl. microdosing, ketamine), cannabis, mental health
ContactNiloufar PouyanUSA
University of Michigan·Mechanisms of therapeutic action; Domain-based, neuroscience-informed investigation of psychedelics in psychiatric conditions and chronic pain
ContactPaul LiknaitzkyAustralia
Monash University, Australia·Clinical trials, psychedelic psychotherapies, psychedelic-catalysed insight, therapist training, psychedelic-assisted training, extended uses of PAT
ContactPedram Dara
Psychedelic Lived Experiences·Lived experience expertise (clinical trial participants and patients)
ContactPedro TeixeiraPortugal
University of Lisbon - Faculty of Human Kinetics·Psychedelics, health behaviors, prevention, public health
ContactPinni (Pinchas) BaumolIsrael
Tel-aviv University, Shaare Nefesh resilience center, ACPT·PAT for PTSD/Harm reduction/Policy change social work
ContactRick HarrisUSA
University of California, Irvine·Psychedelics for chronic pain and opioid addiction
ContactRotem PetrankerCanada
Canadian Centre for Psychedelic Science AND ALSO McMaster University·Psychedelics; microdosing; open science; methodology; clinical trial design
ContactSam LashamNew Zealand
University of Auckland, New Zealand, Students for Sensible Drug Policy Aotearoa New Zealand·Real world use of psychedelics, harm reduction, drug checking, and beneficial illicit drug use
ContactSara de la SalleCanada
McGill University·Psychedelics and music, mindfulness, absorption, imprinting (visual hallucinations)
ContactSue-Ling ChangCanada
Centre de recherche du CHU de Québec-Université Laval, Québec, Canada·Palliative care, psilocybin-assisted therapy, epidemiology
ContactToshihiko MatsumotoJapan
Department of Drug Dependence Research at the National Center of Neurology and Psychiatry (NCNP), Japan·Substance Use Disorder treatment, Harm Reduction, Policy, Psychedelic use in Japan
ContactTúlio Pereira Alvarenga e CastroBrazil
Universidade Federal dos Vales do Jequitinhonha e Mucuri·DMT; Psilocybin; psychiatry; addiction medicine; medical anthropology; community; traditional healing; nature relatedness
ContactVincent JoralemonUSA
Director, Berkeley Law Life Sciences Law & Policy Center·FDA Approval, patents, commercialization, decriminalization, policy, federalism
ContactZach WalshCanada
University of British Columbia·psychedelics and cannabis for problematic substance use; psychedelic access
ContactShowing 44 consortium members
